- Etravirine (tradename Intelence, developed as TMC-125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
- Standard adult dose: 2 x 100 mg tablets, twice daily or 1 x 200 mg tablet twice daily. NOTE: higher and lower doses are used in combination with some other HIV drugs.
- Etravirine can be dispersed in water before being taken. This is similar to being dissolved.
- Etravirine needs to be taken with a meal. Without food drug levels are reduced by 50%. However, the type of food is not specified.
- Side effects: rash, nausea, liver problems.
- Other notes: etravirine is active in many people who developed resistance to either nevirapine or efavirenz. For this reason it is not generally used for first-line treatment in the UK. Etravirine interacts with many other HIV drugs. It can not be taken with other NNRTIs or with many protease inhibitors. It is most commonly used in combinations that include either two nucleosides and/or darunavir/ritonavir.
The European patient information and detailed Product Information for etravirine are available in PDF format from this link at the European Medicines Agency (EMA) website.
The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.
The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.